Startseite The crystal structure of 3-nitrobenzene-1,2-dicarboxylic acid—pyrazine-2-carboxamide(1/1), C13H10N4O7
Artikel Open Access

The crystal structure of 3-nitrobenzene-1,2-dicarboxylic acid—pyrazine-2-carboxamide(1/1), C13H10N4O7

  • Cheng-Jun Jiang ORCID logo EMAIL logo , Die Cheng , Ying-Fan Xia ORCID logo , Jia-rong Zhang und Shu-ting Lin
Veröffentlicht/Copyright: 1. November 2022
Artikel downloaden (PDF)
Veröffentlichen auch Sie bei De Gruyter Brill
Manuskript einreichen Informationen für Autor*innen
Zeitschrift für Kristallographie - New Crystal Structures
Aus der Zeitschrift Zeitschrift für Kristallographie - New Crystal Structures Band 238 Heft 1

Abstract

C13H10N4O7, monoclinic, P21/n (no. 14), a = 10.7017(7) Å, b = 7.1240(5) Å, c = 19.0878(13) Å, β = 99.280(3)°, V = 1436.19(17) Å3, Z = 4, Rgt (F) = 0.0586, wRref (F 2) = 0.1746, T = 296.15 K.

CCDC no.: 2206393

The molecular structure is shown in the figure. Table 1 contains crystallographic data and Table 2 contains the list of the atoms including atomic coordinates and displacement parameters.

Table 1:

Data collection and handling.

Crystal: Colourless block
Size: 0.48 × 0.35 × 0.29 mm
Wavelength: Mo Kα radiation (0.71073 Å)
μ: 0.13 mm−1
Diffractometer, scan mode: Bruker D8 Venture, φ and ω
θ max, completeness: 27.2°, >99 %
N(hkl)measured, N(hkl)unique, R int: 20,755, 3189, 0.034
Criterion for I obs, N(hkl) gt: I obs > 2σ(I obs), 2684
N(param)refined: 219
Programs: Bruker [1], Olex2 [2], SHELX [3, 4]
Table 2:

Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å2).

Atom x y z U iso*/U eq
O1 0.56030 (14) 0.6521 (2) 0.80568 (8) 0.0554 (4)
N1 0.39272 (16) 1.0651 (2) 0.83422 (10) 0.0491 (4)
N2 0.60064 (18) 1.1038 (3) 0.94184 (10) 0.0539 (5)
N3 0.36314 (15) 0.7425 (2) 0.75681 (9) 0.0475 (4)
H3A 0.352312 0.647621 0.728643 0.057*
H3B 0.303967 0.824517 0.756137 0.057*
C1 0.4089 (2) 1.2159 (3) 0.87595 (14) 0.0618 (6)
H1 0.349051 1.311502 0.868907 0.074*
C2 0.5118 (2) 1.2347 (3) 0.92937 (13) 0.0597 (6)
H2 0.518990 1.342165 0.957370 0.072*
C3 0.58626 (19) 0.9533 (3) 0.89993 (10) 0.0463 (5)
H3C 0.647217 0.859162 0.906400 0.056*
C4 0.48247 (16) 0.9344 (2) 0.84700 (9) 0.0371 (4)
C5 0.47010 (17) 0.7623 (3) 0.80088 (10) 0.0382 (4)
O2 0.38517 (13) 0.3770 (2) 0.68504 (8) 0.0546 (4)
O3 0.58489 (14) 0.3501 (3) 0.73787 (10) 0.0666 (5)
H3 0.570195 0.452311 0.754514 0.100*
O4 0.19355 (13) 0.1258 (2) 0.59364 (8) 0.0515 (4)
O5 0.31431 (14) 0.2893 (2) 0.53055 (8) 0.0550 (4)
H5 0.246717 0.335789 0.512353 0.083*
O6 0.2637 (2) −0.0980 (3) 0.48266 (13) 0.1094 (10)
O7 0.3765 (2) −0.3365 (3) 0.48143 (12) 0.0877 (7)
N4 0.35091 (17) −0.1942 (2) 0.50934 (9) 0.0474 (4)
C6 0.50408 (16) 0.1122 (3) 0.65828 (9) 0.0374 (4)
C7 0.41254 (16) 0.0484 (2) 0.60224 (9) 0.0350 (4)
C8 0.43686 (17) −0.1239 (3) 0.57199 (9) 0.0383 (4)
C9 0.54172 (19) −0.2334 (3) 0.59650 (11) 0.0460 (5)
H9 0.552355 −0.349845 0.576264 0.055*
C10 0.6298 (2) −0.1668 (3) 0.65125 (11) 0.0507 (5)
H10 0.701304 −0.237663 0.668069 0.061*
C11 0.61190 (18) 0.0054 (3) 0.68128 (10) 0.0463 (5)
H11 0.672964 0.050936 0.717525 0.056*
C12 0.48513 (17) 0.2934 (3) 0.69422 (10) 0.0396 (4)
C13 0.29354 (16) 0.1587 (2) 0.57572 (9) 0.0364 (4)

Source of materials

The mixture of pyrazinamide and 3-nitrophthalic acid with a molar ratio of 1:1 was dissolved in deionized water, and the resulting mixed solution was stirred and dissolved in a constant temperature water bath at 30 °C to obtain a clear solution. The solution was filtered and placed in a sample vial, covered with membrane and punctured. The filtrate was slowly evaporated at room temperature to obtain crystals of the title compound.

Experimental details

Absorption corrections were applied by using multi-scan program [1]. Using Olex2 [2], the structure was solved with the ShelXT [3] structure solution program and refined with the ShelXL [4] refinement package. The H atoms were fixed, fixed U iso were set to 1.2 times of all C(H) groups and N(H, H) groups; 1.5 times of O(H) groups.

Comment

Pyrazinamide (PZA), a white crystalline powder, is the first-line drug for the treatment of pulmonary tuberculosis and the most effective antibacterial drug in short-course chemotherapy. Due to the low water solubility (15 μg/mL) and low bioavailability, its oral absorption effect is severely inhibited [5]. In recent years, drug co-crystal technology, as an emerging technology, enhances the efficacy of drugs by improving the solubility and permeability of drugs [6]. Therefore, PZA can be co-crystallized to improve its solubility and bioavailability. Cocrystals of pyrazinamide were obtained with 3-(4-hydroxyphenyl)prop-2-enoic acid (CCDC: 2026373, JAJYUS), thiophene-2,5-dicarboxylic acid (CCDC: 2026372, JAJZON), 2,6-dichlorobenzoic acid (CCDC: 2026371, JAJZED), 5-hydroxybenzene-1,3-dicarboxylic acid (CCDC: 2069727, JAJZIH) [7], hydrochlorothiazide (CCDC: 1510703, EGENIP01) [8], 4-nitrobenzoic acid (CCDC: 963629, MUDVUE) [9] and so on.

In the title crystal, the main intermolecular force is the formation of hydrogen bonds. The O2 atom on the carboxyl groups of 3-nitrophthalic acid is a hydrogen bond acceptor. The H3A and H3B atoms on the amide group (N3–H3) of the pyrazinamide molecule are hydrogen bond donors, forming the intermolecular hydrogen bond N3–H3A⋯O2 [length 2.969(2) Å, angle 138.0°]. The O1 atom on the amide group of the pyrazinamide molecule is a hydrogen bond acceptor, and the H2 atom on the carboxyl group (O3–H3) of the 3-nitrophthalic acid molecule is a hydrogen bond donor, forming the intermolecular hydrogen bond O3–H3⋯O1 [length 2.546(2) Å, angle 167.8°]. The N1 atom on the pyrazine ring of the pyrazinamide molecule is a hydrogen bond acceptor, the H5 atom on the carboxyl group (O5–H5) of the 3-nitrophthalic acid molecule is a hydrogen bond donor, forming an intermolecular hydrogen bond O3–H3⋯O1 (symmetry code: −1/2 + x, 3/2 − y, −1/2 + z) [length 2.725(2) Å, angle 160.2°].

Corresponding author: Cheng-Jun Jiang, School of Biological and Chemical Engineering, Zhejiang University of Science and Technology, Liuhe Road 318#, Hangzhou, China, E-mail:

Funding source: Zhejiang Provincial Natural Science Foundation of China http://dx.doi.org/10.13039/501100010248

Award Identifier / Grant number: LGJ20B060001

Acknowledgements

We gratefully acknowledge support by the Zhejiang Province Basic Public Welfare Research Project (LGJ20B060001).

  1. Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

  2. Research funding: This work was financially supported by Zhejiang Provincial Natural Science Foundation of China (grant number: LGJ20B060001).

  3. Conflict of interest statement: The authors declare no conflicts of interest regarding this article.

References

1. Bruker. Apex3 v. 2016.9-0 and SAINT v. 8.37A; Bruker Axs Inc.: Madison, Wisconsin, USA, 2016.Suche in Google Scholar

2. Dolomanov, O. V., Bourhis, L. J., Gildea, R. J., Howard, J. A. K., Puschmann, H. OLEX2: a complete structure solution, refinement and analysis program. J. Appl. Crystallogr. 2009, 42, 339–341; https://doi.org/10.1107/s0021889808042726.Suche in Google Scholar

3. Sheldrick, G. M. SHELXTL – integrated space-group and crystal-structure determination. Acta Crystallogr. 2015, A71, 3–8; https://doi.org/10.1107/s2053273314026370.Suche in Google Scholar PubMed PubMed Central

4. Sheldrick, G. M. Crystal structure refinement with SHELXL. Acta Crystallogr. 2015, C71, 3–8; https://doi.org/10.1107/s2053229614024218.Suche in Google Scholar

5. Wang, J. R., Ye, C., Zhu, B., Zhou, C., Mei, X. Pharmaceutical cocrystals of the anti-tuberculosis drug pyrazinamide with dicarboxylic and tricarboxylic acids. CrystEngComm 2015, 17, 747–752; https://doi.org/10.1039/c4ce02044h.Suche in Google Scholar

6. Rajendran, M. A., Allada, R., Sajid, S. S. Co-crystals for generic pharmaceuticals: an outlook on solid oral dosage formulations. Recent Adv. Drug Deliv. Formul. 2021, 15, 15–36; https://doi.org/10.2174/2667387815666210203151209.Suche in Google Scholar PubMed

7. Yang, X., Zhu, J., Chen, Z., Chen, B., Jin, S., Liu, B., Wang, D. Seven cocrystals of pyrazinamide and organic acids by H-bonds and some noncovalent associations. J. Mol. Struct. 2022, 1250, 131770; https://doi.org/10.1016/j.molstruc.2021.131770.Suche in Google Scholar

8. Gopi, S. P., Banik, M., Desiraju, G. R. New cocrystals of hydrochlorothiazide: optimizing solubility and membrane diffusivity. Cryst. Growth Des. 2017, 17, 308–316; https://doi.org/10.1021/acs.cgd.6b01540.Suche in Google Scholar

9. Abourahma, H., Shah, D. D., Melendez, J., Johnson, E. J., Holman, K. T. A tale of two stoichiometrically diverse cocrystals. Cryst. Growth Des. 2015, 15, 3101–3104; https://doi.org/10.1021/acs.cgd.5b00357.Suche in Google Scholar
Received: 2022-09-21
Accepted: 2022-10-11
Published Online: 2022-11-01
Published in Print: 2023-01-27

© 2022 the author(s), published by De Gruyter, Berlin/Boston

This work is licensed under the Creative Commons Attribution 4.0 International License.

Artikel in diesem Heft

  1. Frontmatter
  2. New Crystal Structures
  3. Crystal structure of undecacalcium decaarsenide, Ca11As10
  4. Crystal structure of catena-poly[diiodido-(μ2-1,5-dimethyl-2-phenyl-4-((pyridin-4- ylmethylene)amino)-1,2-dihydro-3H -pyrazol-3-one-κ2 N: O)zinc(II)], C17H16I2N4OZn
  5. The crystal structure of 5,10,15,20-tetrakis(4-(tert-butyl)phenyl)porphyrin-21,23-diido-κ4 N 4-naphthalocyanido-κ4 N 4-neodymium(IV) - chloroform (1/6) C114H90N12Cl18Nd
  6. The crystal structure of 1-(4-bromophenyl)-3-(2-chlorobenzyl)urea, C14H12BrClN2O
  7. Crystal structure of bis[benzyl(methyl)carbamodithioato-κ 2 S,S′]-di-n-butyltin(IV), C26H38N2S4Sn
  8. Crystal structure of (E)-3-(2-(4-(diethylamino)-2-hydroxystyryl)-3,3-dimethyl-3H-indol-1-ium-1-yl)propane-1-sulfonate – methanol (1/2), C25H32N2O4S⋅2CH3OH
  9. Synthesis and crystal structure of {(N′,N″-(((ethane-1,2-diylbis(oxy))bis(2,1-phenylene))-bis(methaneylylidene))bis(2-hydroxybenzohydrazonato)-κ6 N 2 O 4}copper(II), C30H24CuN4O6
  10. The crystal structure of ((E)-2,4-dibromo-6-(((5-(nitro)-2-oxidophenyl)imino)methyl)phenolato-κ 3 N,O,O′)tris(pyridine-κN)manganese(II), C28H21Br2MnN5O4
  11. Synthesis and crystal structure of 1-((3R,10S,13R,17S)-10,13-dimethyl-3-(p-tolylamino)hexadecahydro-1H-cyclopenta-[a]phenanthren-17-yl)ethan-1-one, C28H41NO
  12. The crystal structure of 3-nitrobenzene-1,2-dicarboxylic acid—pyrazine-2-carboxamide(1/1), C13H10N4O7
  13. Crystal structure of poly[tetrakis(μ3-2-aminonicotinato-κ3N,O,O′)-(μ2-oxalato-κ4 O,O′:O″,O′″)-(μ4-oxalato-κ6 N:N′:O,O′:O″,O′″)dicopper(I)-disamarium(III)], [SmCu(C6N2H5O2)2(C2O4)] n
  14. The crystal structure of 2,3,4-trihydroxybenzoic- acid—pyrazine-2-carboxamide—water (1/1/1), C12H13N3O7
  15. Crystal structure of N-ethyl-4-[3-(trifluoromethyl)-phenyl]piperazine-1-carbothioamide, C14H18F3N3S
  16. The crystal structure of 3-anilino-1,4-diphenyl-4H-1,2,4-triazol-1-ium iodide, C20H17N4I
  17. The crystal structure of (tris(2-benzimidazolylmethyl)amine)-benzoato-copper(II) perchlorate monohydrate, CuC31H28N7O7Cl
  18. Crystal structure of [2-hydroxy-3-methyl-benzoato-k1 O-triphenyltin(IV)], C26H22O3Sn
  19. Crystal structure of diaqua-bis(4-(hydroxymethyl)-benzoato-k1 O)zinc(II), C16H18O8Zn
  20. The crystal structure of dicarbonyl-(N-nitroso-N-oxido-phenylamine-κ 2 O,O)-rhodium(I), C8H5N2O4Rh
  21. The crystal structure of oxalic acid – 2-ethoxybenzamide (2/1), C20H24N2O8
  22. The crystal structure of ethyl 7-ethyl-5-methyl-4,7-dihydrotetrazolo[1,5-a]pyrimidine-6-carboxylate, C10H15N5O2
  23. Crystal structure of poly[(N,N-dimethylacetamide-κO) (μ4-2-nitroisophthalato-κ 4 O:O′:O″:O′″)manganese(II)], C11H10N2O7Mn
  24. Crystal structure of 14-O-acetyldelcosine, C26H41NO8
  25. The crystal structure of poly[(1,10-phenanthroline-κ2 N,N′)-(μ 4-2-chlorobenzene-1,3-dicarboxylato-κ5 O:O′:O″:O‴) cadmium(II)] monohydrate, C20H13CdClN2O5
  26. Crystal structure of propane-1,3-diylbis(diphenylphosphine sulfide) ethanol solvate, C27H26P2S2
  27. Crystal structure of bis{[(4-diethylamino-2-hydroxy-benzylidene)-hydrazinocarbonylmethyl]-trimethylammonium} tetrabromozincate, C32H54N8O4ZnBr4
  28. Synthesis and crystal structure of dimethyl 2,2′-(2,5-bis(4-hydroxyphenyl)-2,5-dihydrofuran-3,4-diyl)dibenzoate, C34H30O7
  29. Synthesis and crystal structure of 2-(2-oxo-2-phenylethyl)-4H-chromen-4-one, C17H12O3
  30. The crystal structure of tetra(imidazole-κ1 N)zinc(II) μ2-oxido-hexaoxido-divanadium(VI) C12H16N8O6V2Zn
  31. Crystal structure of S-2-(1-(5-methylpyridin-2-ylamino)octyl)-3-hydroxynaphthalene-1,4-dione, C24H28N2O3
  32. Crystal structure of bis(μ2-5-chloro-2-oxido-N-(1-oxido-2-oxo-2-phenylethylidene)-benzohydrazonato-κ5 N,O,O′:N′,O′′)-oktakis(pyridine-κ1 N)trinickel(II) – methanol – pyridine (1/1/1) C76H65N13Cl2Ni3O9
  33. The crystal structure of methyl 3,5-diaminobenzoate, C8H10N2O2
  34. Crystal structure of 10-(9H-carbazol-9-yl)-5H-dibenzo[a,d][7]annelen-5-one, C27H17NO
  35. Crystal structure of ethyl 1-(2-hydroxyethyl)-4-((4-methoxyphenyl)amino)-5-oxo-2,5-dihydro-1H-pyrrole-3-carboxylate, C16H20N2O5
  36. The crystal structure of 1-(4-bromophenyl)-3-cycloheptylurea, C14H19BrN2O
  37. The crystal structure of 1,4-bis(1,2,3,4,5-pentamethylcyclopenta-2,4-dien-1-yl)-3,6-bis ((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methylene)-1,4-dialuminacyclohexane – benzene (1/2), C50H72Al2B2O4
  38. Crystal structure of bis(μ 3-diphenylphosphinato)-tetrakis(μ 2-diphenylphosphinato)-bis(diphenylphosphinato)-bis(μ 2-hydroxo)dicopper(II)-ditin(IV), C104H100O18P8Cu2Sn2
  39. Crystal structure of 3-((3,4-dichloroisothiazol-5-yl)methoxy)benzo[d] isothiazole 1,1-dioxide, C11H6Cl2N2O3S2
  40. Synthesis and crystal structure of 2-(2-(2-fluorophenyl)-2-oxoethyl)-4H-chromen-4-one, C17H11FO3
  41. The crystal structure of tris(carbonyl)-bis(carbonyl)-[μ-propane-1,2- dithiolato]-(benzyldiphenylphosphine)diiron (Fe—Fe), C27H23Fe2O5PS2
  42. Crystal structure of 1-(2-(4-chlorophenethyl)-2-hydroxy-3,3-dimethylbutyl)-1H-1,2,4-triazol-4-ium nitrate, C16H23N4O4Cl
  43. The crystal structure of 3,3′-disulfanediyldi(1H-1,2,4-triazol-5-amine) monohydrate, C4H8N8OS2
  44. The crystal structure of trans-[bis(4-methylpyridine-κN)bis(quinoline-2-carboxylato- κ 2 N,O)cadmium(II)], C32H26CdN4O4
  45. The crystal structure of ethyl 2′-hydroxy-4′,6′-dimethoxy-3-(4-methoxynaphthalen-1-yl)-5-oxo-2,3,4,5-tetrahydro-[1,1′-biphenyl]-4-carboxylate, C28H28O7
https://doi.org/10.1515/ncrs-2022-0462
Creative Commons
BY 4.0

Artikel in diesem Heft

  1. Frontmatter
  2. New Crystal Structures
  3. Crystal structure of undecacalcium decaarsenide, Ca11As10
  4. Crystal structure of catena-poly[diiodido-(μ2-1,5-dimethyl-2-phenyl-4-((pyridin-4- ylmethylene)amino)-1,2-dihydro-3H -pyrazol-3-one-κ2 N: O)zinc(II)], C17H16I2N4OZn
  5. The crystal structure of 5,10,15,20-tetrakis(4-(tert-butyl)phenyl)porphyrin-21,23-diido-κ4 N 4-naphthalocyanido-κ4 N 4-neodymium(IV) - chloroform (1/6) C114H90N12Cl18Nd
  6. The crystal structure of 1-(4-bromophenyl)-3-(2-chlorobenzyl)urea, C14H12BrClN2O
  7. Crystal structure of bis[benzyl(methyl)carbamodithioato-κ 2 S,S′]-di-n-butyltin(IV), C26H38N2S4Sn
  8. Crystal structure of (E)-3-(2-(4-(diethylamino)-2-hydroxystyryl)-3,3-dimethyl-3H-indol-1-ium-1-yl)propane-1-sulfonate – methanol (1/2), C25H32N2O4S⋅2CH3OH
  9. Synthesis and crystal structure of {(N′,N″-(((ethane-1,2-diylbis(oxy))bis(2,1-phenylene))-bis(methaneylylidene))bis(2-hydroxybenzohydrazonato)-κ6 N 2 O 4}copper(II), C30H24CuN4O6
  10. The crystal structure of ((E)-2,4-dibromo-6-(((5-(nitro)-2-oxidophenyl)imino)methyl)phenolato-κ 3 N,O,O′)tris(pyridine-κN)manganese(II), C28H21Br2MnN5O4
  11. Synthesis and crystal structure of 1-((3R,10S,13R,17S)-10,13-dimethyl-3-(p-tolylamino)hexadecahydro-1H-cyclopenta-[a]phenanthren-17-yl)ethan-1-one, C28H41NO
  12. The crystal structure of 3-nitrobenzene-1,2-dicarboxylic acid—pyrazine-2-carboxamide(1/1), C13H10N4O7
  13. Crystal structure of poly[tetrakis(μ3-2-aminonicotinato-κ3N,O,O′)-(μ2-oxalato-κ4 O,O′:O″,O′″)-(μ4-oxalato-κ6 N:N′:O,O′:O″,O′″)dicopper(I)-disamarium(III)], [SmCu(C6N2H5O2)2(C2O4)] n
  14. The crystal structure of 2,3,4-trihydroxybenzoic- acid—pyrazine-2-carboxamide—water (1/1/1), C12H13N3O7
  15. Crystal structure of N-ethyl-4-[3-(trifluoromethyl)-phenyl]piperazine-1-carbothioamide, C14H18F3N3S
  16. The crystal structure of 3-anilino-1,4-diphenyl-4H-1,2,4-triazol-1-ium iodide, C20H17N4I
  17. The crystal structure of (tris(2-benzimidazolylmethyl)amine)-benzoato-copper(II) perchlorate monohydrate, CuC31H28N7O7Cl
  18. Crystal structure of [2-hydroxy-3-methyl-benzoato-k1 O-triphenyltin(IV)], C26H22O3Sn
  19. Crystal structure of diaqua-bis(4-(hydroxymethyl)-benzoato-k1 O)zinc(II), C16H18O8Zn
  20. The crystal structure of dicarbonyl-(N-nitroso-N-oxido-phenylamine-κ 2 O,O)-rhodium(I), C8H5N2O4Rh
  21. The crystal structure of oxalic acid – 2-ethoxybenzamide (2/1), C20H24N2O8
  22. The crystal structure of ethyl 7-ethyl-5-methyl-4,7-dihydrotetrazolo[1,5-a]pyrimidine-6-carboxylate, C10H15N5O2
  23. Crystal structure of poly[(N,N-dimethylacetamide-κO) (μ4-2-nitroisophthalato-κ 4 O:O′:O″:O′″)manganese(II)], C11H10N2O7Mn
  24. Crystal structure of 14-O-acetyldelcosine, C26H41NO8
  25. The crystal structure of poly[(1,10-phenanthroline-κ2 N,N′)-(μ 4-2-chlorobenzene-1,3-dicarboxylato-κ5 O:O′:O″:O‴) cadmium(II)] monohydrate, C20H13CdClN2O5
  26. Crystal structure of propane-1,3-diylbis(diphenylphosphine sulfide) ethanol solvate, C27H26P2S2
  27. Crystal structure of bis{[(4-diethylamino-2-hydroxy-benzylidene)-hydrazinocarbonylmethyl]-trimethylammonium} tetrabromozincate, C32H54N8O4ZnBr4
  28. Synthesis and crystal structure of dimethyl 2,2′-(2,5-bis(4-hydroxyphenyl)-2,5-dihydrofuran-3,4-diyl)dibenzoate, C34H30O7
  29. Synthesis and crystal structure of 2-(2-oxo-2-phenylethyl)-4H-chromen-4-one, C17H12O3
  30. The crystal structure of tetra(imidazole-κ1 N)zinc(II) μ2-oxido-hexaoxido-divanadium(VI) C12H16N8O6V2Zn
  31. Crystal structure of S-2-(1-(5-methylpyridin-2-ylamino)octyl)-3-hydroxynaphthalene-1,4-dione, C24H28N2O3
  32. Crystal structure of bis(μ2-5-chloro-2-oxido-N-(1-oxido-2-oxo-2-phenylethylidene)-benzohydrazonato-κ5 N,O,O′:N′,O′′)-oktakis(pyridine-κ1 N)trinickel(II) – methanol – pyridine (1/1/1) C76H65N13Cl2Ni3O9
  33. The crystal structure of methyl 3,5-diaminobenzoate, C8H10N2O2
  34. Crystal structure of 10-(9H-carbazol-9-yl)-5H-dibenzo[a,d][7]annelen-5-one, C27H17NO
  35. Crystal structure of ethyl 1-(2-hydroxyethyl)-4-((4-methoxyphenyl)amino)-5-oxo-2,5-dihydro-1H-pyrrole-3-carboxylate, C16H20N2O5
  36. The crystal structure of 1-(4-bromophenyl)-3-cycloheptylurea, C14H19BrN2O
  37. The crystal structure of 1,4-bis(1,2,3,4,5-pentamethylcyclopenta-2,4-dien-1-yl)-3,6-bis ((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methylene)-1,4-dialuminacyclohexane – benzene (1/2), C50H72Al2B2O4
  38. Crystal structure of bis(μ 3-diphenylphosphinato)-tetrakis(μ 2-diphenylphosphinato)-bis(diphenylphosphinato)-bis(μ 2-hydroxo)dicopper(II)-ditin(IV), C104H100O18P8Cu2Sn2
  39. Crystal structure of 3-((3,4-dichloroisothiazol-5-yl)methoxy)benzo[d] isothiazole 1,1-dioxide, C11H6Cl2N2O3S2
  40. Synthesis and crystal structure of 2-(2-(2-fluorophenyl)-2-oxoethyl)-4H-chromen-4-one, C17H11FO3
  41. The crystal structure of tris(carbonyl)-bis(carbonyl)-[μ-propane-1,2- dithiolato]-(benzyldiphenylphosphine)diiron (Fe—Fe), C27H23Fe2O5PS2
  42. Crystal structure of 1-(2-(4-chlorophenethyl)-2-hydroxy-3,3-dimethylbutyl)-1H-1,2,4-triazol-4-ium nitrate, C16H23N4O4Cl
  43. The crystal structure of 3,3′-disulfanediyldi(1H-1,2,4-triazol-5-amine) monohydrate, C4H8N8OS2
  44. The crystal structure of trans-[bis(4-methylpyridine-κN)bis(quinoline-2-carboxylato- κ 2 N,O)cadmium(II)], C32H26CdN4O4
  45. The crystal structure of ethyl 2′-hydroxy-4′,6′-dimethoxy-3-(4-methoxynaphthalen-1-yl)-5-oxo-2,3,4,5-tetrahydro-[1,1′-biphenyl]-4-carboxylate, C28H28O7
Jetzt anmelden und 20% sparen
Institutioneller Zugang
Wie funktioniert Authentifizierung?
Haben Sie eine Idee, wie wir unsere Website verbessern können?
Bitte schreiben Sie uns.
© 2025 De Gruyter Brill
Heruntergeladen am 15.11.2025 von https://www.degruyterbrill.com/document/doi/10.1515/ncrs-2022-0462/html?lang=de
Button zum nach oben scrollen